A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-29 and is reviewed periodically as new material appears.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
==== Acid pigmentation ==== In 2009 Luigi Garlaschelli, professor of organic chemistry at the University of Pavia, stated that he had made a full-size reproduction of the Shroud of Turin using only medieval technologies. His cloth was woven in the exact same manner and herringbone pattern by yarn type and weight as the Shroud. Garlaschelli placed a linen sheet over a volunteer and then rubbed it with an acidic pigment for the body. The shroud was then aged in an oven before being washed to remove the pigment. He then added blood stains, scorches and water stains to replicate the original. Giulio Fanti, professor of mechanical and thermic measurements at the University of Padua, commented that "the technique itself seems unable to produce an image having the most critical Turin Shroud image characteristics". Garlaschelli noted that the microscopic properties of his reproductions can't be exactly identical to the original, as accelerated and artificial aging lasting 4 hours cannot replicate the natural centuries the Shroud of Turin has gone through. He therefore considered the criticisms of those who claim a need for an absolute similarity as specious. Garlaschelli's reproduction was shown in a 2010 National Geographic documentary. Garlaschelli's technique included the bas-relief approach (described below) but only for the image of the face. The resultant image was visibly similar to the Turin Shroud, though lacking the uniformity and detail of the original.
Ginkgo has long been cultivated in China. It is common in the southern third of the country. Some planted trees at temples are believed to be over 1,500 years old. The first record of Europeans encountering it is in 1690 in Japanese temple gardens, where the tree was seen by the German botanist Engelbert Kaempfer. Because of its status in Buddhism and Confucianism, the ginkgo has also been widely planted in Korea and in Japan since the 14th century; in both areas, some naturalization has occurred, with ginkgos seeding into natural forests. Ginkgo has been commonly cultivated in North America for over 200 years and in Europe for close to 300, but during that time, it has never become significantly naturalized. G. biloba is also commonly manually planted in cities across the United States and Europe. This species is highly tolerant to pollution and serves as a visually appealing, shade-providing tree in many cities and gardens. Many intentionally planted ginkgos are male cultivars grafted onto plants propagated from seed, because the male trees will not produce the malodorous seeds. The popular cultivar 'Autumn Gold' is a clone of a male plant. The disadvantage of male Ginkgo biloba trees is that their pollen is highly allergenic. They have an OPALS (Ogren Plant Allergy Scale) rating of 7 (out of 10), whereas female trees, which can produce no pollen, have an OPALS allergy scale rating of 2.
ATP + Creatine → H+ + ADP + CP (Mg2+ assisted, catalyzed by creatine kinase) ADP + Pi → ATP (during anaerobic glycolysis and oxidative phosphorylation) AMP can dephosphorylate to adenosine and diffuse out of the cell; the purine nucleotide cycle may therefore also reduce the loss of adenosine from the cell since nucleosides permeate cell membranes, whereas nucleotides do not.
In the 1930s and early-1940s, U.S. President Franklin D. Roosevelt voiced strong support to the Indian independence movement despite being allies with Britain. The first significant immigration from India before 1965 involved Sikh farmers going to California in the early twentieth century.
=== Association with famine === Ingestion of legumes containing the toxin occurs despite an awareness of the means to detoxify Lathyrus. Drought conditions can lead to shortages of both fuel and water, preventing the necessary detoxification steps from being taken, particularly in impoverished countries. Lathyrism usually occurs where the combination of poverty and food insecurity leaves few other food options.
Sources: en.wikipedia.org
Actin filaments, the thin filaments, are the major component of the I-band and extend into the A-band. Myosin filaments, the thick filaments, are bipolar and extend throughout the A-band. They are cross-linked at the centre by the M-band. The giant protein titin (connectin) extends from the Z-line of the sarcomere, where it binds to the thick filament (myosin) system, to the M-band, where it is thought to interact with the thick filaments. Titin (and its splice isoforms) is the biggest single highly elasticated protein found in nature. It provides binding sites for numerous proteins and is thought to play an important role as sarcomeric ruler and as blueprint for the assembly of the sarcomere. Another giant protein, nebulin, is hypothesised to extend along the thin filaments and the entire I-Band. Similar to titin, it is thought to act as a molecular ruler along for thin filament assembly. Several proteins important for the stability of the sarcomeric structure are found in the Z-line as well as in the M-band of the sarcomere. Actin filaments and titin molecules are cross-linked in the Z-disc via the Z-line protein alpha-actinin. The M-band proteins myomesin as well as C-protein crosslink the thick filament system (myosins) and the M-band part of titin (the elastic filaments). The M-line also binds creatine kinase, which facilitates the reaction of ADP and phosphocreatine into ATP and creatine. The interaction between actin and myosin filaments in the A-band of the sarcomere is responsible for the muscle contraction (based on the sliding filament model).
To reduce the transport of heavier raw materials and to minimize the associated costs, it is more economical to build cement plants closer to the limestone quarries rather than to the consumer centers. As of 2025 carbon capture and storage is emerging as a way to decarbonise cement production. French company Air Liquide was granted EU funding for two CCS projects in Kujawy (Poland)and the K6 Program aimed at producing the first carbon neutral cement in Europe in Lumbres, France. The projects are expected to start operation between by 2028 and capture 18.1 MtCO2 emissions over a decade.
=== Etymology === Lymph originates in the Classical Latin word lympha "water", which is also the source of the English word limpid. The spelling with y and ph was influenced by folk etymology with Greek νύμϕη (nýmphē) "nymph". The adjective used for the lymph-transporting system is lymphatic. The adjective used for the tissues where lymphocytes are formed is lymphoid. Lymphatic comes from the Latin word lymphaticus, meaning "connected to water."
Intrathecal/intraventricular administration: Chemotherapy is injected directly into the cerebrospinal fluid, either through a lumbar puncture or a surgically implanted catheter. Intracerebral implants: A neurosurgeon creates a cavity within a tumor to allow the placement of dime-sized chemotherapy wafers, such as Gliadel wafers. Several of these wafers can be placed at the time of surgery and will release the chemotherapy agent carmustine slowly over time. This provides a much higher concentration of chemotherapy in the brain than can be obtained with intravenous administration, and it causes fewer systemic side effects. However, it is an option only for patients with surgically resectable tumours; it cannot be used to treat DIPG. Osmotic blood–brain barrier disruption (BBBD): The cells of the blood–brain barrier are shrunk by a concentrated sugar solution (mannitol). This opens the barrier and allows 10 to 100 times more chemotherapy to enter the brain. A catheter is placed into a large artery (usually the one in the groin called the femoral artery) and threaded up to the carotid or vertebral artery. The hypertonic mannitol is injected, followed by a chemotherapeutic agent. Patients spend a few days in the hospital for each administration. This has been attempted with DIPG tumours. Convection-enhanced delivery: Chemotherapy is delivered to the tumour by a surgically implanted catheter under a pressure gradient to achieve more distribution than with diffusion alone. Limited experiments have been conducted with brain tumors, including one with a DIPG.
=== Dicastery for the Causes of Saints === As part of his 2022 reorganization of the Curia in Praedicate evangelium, Pope Francis renamed the congregation to the Dicastery for the Causes of Saints. It is working on about 1,600 causes, some dating from the 15th century.
Sources: en.wikipedia.org
=== Brittleness === Most salts are very brittle. Once they reach the limit of their strength, they cannot deform malleably, because the strict alignment of positive and negative ions must be maintained. Instead the material undergoes fracture via cleavage. As the temperature is elevated (usually close to the melting point) a ductile–brittle transition occurs, and plastic flow becomes possible by the motion of dislocations.
Klein C, Entian KD (1994). "Genes involved in self-protection against the lantibiotic subtilin produced by Bacillus subtilis ATCC 6633". Appl. Environ. Microbiol. 60 (8): 2793–801. Bibcode:1994ApEnM..60.2793K. doi:10.1128/aem.60.8.2793-2801.1994. PMC 201725. PMID 8085823. JJ; Roelse, J; Howard, JC; Butcher, GW; Hämmerling, GJ; Neefjes, JJ (1994). "Selectivity of MHC-encoded peptide transporters from human, mouse and rat". Nature. 367 (6464): 648–51. Bibcode:1994Natur.367..648M. doi:10.1038/367648a0. PMID 8107849. Binet R, Letoffe S, Ghigo JM, Delepelaire P, Wandersman C (1997). "Protein secretion by Gram-negative bacterial ABC exporters-a review". Gene. 192 (1): 7–11. doi:10.1016/S0378-1119(96)00829-3. PMID 9224868.
The Lord President of the Supreme Court, Salleh Abas, sent a letter of protest to the Agong, which criticised the prime minister for his comments on the judiciary and called for them to be stopped. Mahathir then suspended Salleh for "gross misbehaviour and conduct", ostensibly because the letter was a breach of protocol. A tribunal set up by Mahathir found Salleh guilty and recommended to the Agong that Salleh be dismissed. Five other judges of the court supported Salleh and were suspended by Mahathir. A newly constituted court dismissed Team B's appeal, allowing Mahathir's faction to continue to use the name UMNO. Mahathir suffered a heart attack in early 1989, which later inspired the establishment of the National Heart Institute (IJN) to improve cardiac care in Malaysia. Mahathir was praised for opting to undergo the surgery in his own country. He recovered to lead Barisan Nasional to victory in the 1990 election. Mahathir interpreted the election results as a reflection of the people's desire for a strong government. Semangat 46 failed to make any headway outside Razaleigh's home state of Kelantan. Following his electoral victory, Mahathir established the Domestic Trade and Consumer Affairs Ministry to better address issues related to trade and consumer protection. During the same period, Mahathir led the government in negotiations with Chin Peng and the Communist Party of Malaya (CPM). These efforts culminated in a tripartite peace agreement in Hat Yai between Malaysia, Thailand, and the CPM. According to insiders, the Hat Yai peace accords were initiated by Mahathir.
=== Francis Crick Medal and Lecture === The Francis Crick Medal and Lecture was established in 2003 following an endowment by his former colleague, Sydney Brenner, joint winner of the 2002 Nobel Prize in Physiology and Medicine. The lecture is delivered annually in any field of biological sciences, with preference given to the areas in which Francis Crick himself worked. Importantly, the lectureship is aimed at younger scientists, ideally under 40, or whose career progression corresponds to this age. As of 2019, Crick lectures have been delivered by Julie Ahringer, Dario Alessi, Ewan Birney, Simon Boulton, Jason Chin, Simon Fisher, Matthew Hurles, Gilean McVean, Duncan Odom, Geraint Rees, Sarah Teichmann, M. Madan Babu and Daniel Wolpert.
Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. For example, the JCR also includes a five-year impact factor, which is calculated by dividing the number of citations to the journal in a given year by the number of articles published in that journal in the previous five years.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.